Sign in
Taking people in United StatesNo phase

Modernizing Perinatal Syphilis Testing

Key facts

Who runs it
The University of Texas Health Science Center, Houston
Where
Baltimore, Columbus, Houston, and Los Angeles, United StatesSee the 9 sites
Trial code
Status
Recruiting
People taking part
924 people, planned
Started
2 May 2023
Expected to end
30 Nov 2027
Type of study
Interventional
Treatments tested
  • Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum
  • Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum
  • Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis
Record updated
3 November 2025

Who can take part

Age
Up to 45 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Maternal diagnosis of syphilis by 2021 CDC STI guidelines, irrespective of treatment status; AND viable pregnancy with gestational age ≥ 12 weeks OR postpartum ≤ 96 hours from delivery OR Neonates of pregnancies affected by syphilis ≤ 72 hours of birth
  • Individuals (men and non-pregnant) with syphilis in Harris Health clinic with syphilis

Who cannot take part

  • Planning to move outside of study prior to ND testing
  • Pregnant individuals and neonates who do not meet the criteria of syphilis (false positive)

This trial is currently available in United States.

  • Johns Hopkins UniversityBaltimore, United StatesContact: Jeanne Sheffield, MDTaking people
  • Kennedy Krieger InstituteBaltimore, United StatesContact: Alison Pritchard, PhDTaking people
  • Nationwide Children's HospitalColumbus, United StatesContact: Pablo SanchezTaking people
  • Baylor College of MedicineHouston, United StatesContact: Martha Rac, MDTaking people
  • Christus HealthHouston, United StatesContact: James Hill, MDTaking people
  • Texas Children's HospitalHouston, United StatesContact: Lisa Noll, PhDTaking people
  • The University of Texas Health Science Center at HoustonHouston, United StatesContact: Norma Perez, DOTaking people
  • University of California, Los AngelesLos Angeles, United StatesContact: Karin Best, PhDTaking people
  • University of Southern CaliforniaLos Angeles, United StatesContact: Brendan Grubbs, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to determine the testing performance of real-time quantitative polymerase chain reaction and transcription mediated amplification by comparing test performance of these novel molecular tests to current 2021 CDC CS guidelines for maternal/neonatal dyads at risk for syphilis infection and to determine whether CS is associated with adverse neurodevelopmental outcomes.

The group in the trial

  • Molecular testing for detection of T. pallidum and use of CDC guidelines for diagnosis of syphilisTreatment being tested

    Treatment: Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum, Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum, and Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 November 2025